SCHEMBL4799634

SCHEMBL4799634

[NH]c1ccc(Oc2cnccn2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.62
KMT2A Q03164 2/20 0.54
LTA4H P09960 1/20 0.51
PTGS2 P35354 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HRH3 Q9Y5N1 1/20 0.42
PLAAT3 P53816 1/20 0.40
PLAAT5 Q96KN8 1/20 0.40
PLAAT2 Q9NWW9 1/20 0.40
PLAAT4 Q9UL19 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.38
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
GCK P35557 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789285 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL29415425 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL15955267 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL5317075 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL4799638 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL171894 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL29580801 0.81 KDM4E (0.62) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL4272944 0.80 KDM4E (0.61) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL27259876 0.78 KDM4E (0.58) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2
SCHEMBL920429 0.77 KDM4E (0.57) KDM4EKMT2ALTA4HPTGS2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US claimed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP claimed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US claimed
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US disclosed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US disclosed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US disclosed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP disclosed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 KDM4E 1815/4885KMT2A 3339/4885LTA4H 3680/4885
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 KDM4E 1754/4885KMT2A 3112/4885LTA4H 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.